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Abstract: There is a need for an accessible biomarker that can complement 
current cerebrospinal fluid (CSF) and imaging biomarkers in an accurate 
and early diagnosis of Alzheimer disease (AD). Saliva is a rich source of 
potential biomarkers and proteins related to neurodegenerative disorders 
have been shown to be present in this matrix, including tau. In this 
study, we quantified salivary total tau (t-tau) concentration in 160 
healthy elderly control (HEC), 60 mild cognitive impairment (MCI) and 54 
Alzheimer's disease (AD) participants using ultra-sensitive Single 
molecule array (Simoa) technology. No median difference in salivary t-tau 
concentration was found between AD and MCI or HEC (12.3 ng/L, 9.8 ng/L 
and 9.6 ng/L, respectively, P = 0.219). In addition, there was no 
association of salivary t-tau concentration with neurophysiological 
assessment or structural MRI. Despite a nominal increase in AD, due to 
the large overlaps in concentrations between clinical groups, we conclude 
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ABSTRACT – There is a need for an accessible biomarker that can complement current 
cerebrospinal fluid (CSF) and positron emission tomography (PETimaging) biomarkers in an accurate 
and early diagnosis of Alzheimer disease (AD). Saliva is a rich source of potential biomarkers and 
proteins related to neurodegenerative disorders have been shown to be present in this matrix, 
including tau. In this study, we quantified salivary total tau (t-tau) concentration in 160 healthy elderly 
control (HEC)Alzheimer’s disease (AD), 60 68 mild cognitive impairment (MCI) and 54 53 healthy 
elderly control (HEC)Alzheimer’s disease (AD) participants using ultra-sensitive Single molecule 
array (Simoa) technology. No median difference in sSalivary t-tau concentration was  found 
concentration inbetween AD did not differ fromand MCI or HEC (12.3 ng/L, 9.8 ng/L and 9.6 ng/L, 
respectively, P = 0.219), and the majority of AD cases had tau levels lower than the median in HEC. 
In addition, there was no association of salivary t-tau concentration with neurophysiological 
assessment or structural MRI. Despite a nominal increase in AD, dDue to the large overlaps in 
concentrations between clinical groups, we conclude that salivary t-tau is neither a suitable biomarker 
for AD nor for cognitive impairment. 
 
INTRODUCTION – The diagnosis of Alzheimer’s disease (AD) remains primarily reliant on clinical 
assessment with support of structural imaging. Magnetic resonance imaging (MRI) is more widely 
used in AD-related investigations owing to its superior spatial resolution of regional brain atrophy and 
wide accessibility. Nonetheless, MRI lacks molecular specificity and as such it is downstream from 
the onset of molecular pathology. Advancements in the latest decade have recognised the valuable 
role of both molecular imaging (PET Positron Emission Tomography (PET) imaging of amyloid and 
tau aggregates) and core CSF biomarkers (Aβ42, t-tau and p-tau), which identify AD pathophysiology 
with high accuracy at the preclinical stage. However, both modalities have disadvantages when 
considering widespread implementation of a test for suspected AD in clinical practice or for 
participant selection for therapeutic disease modifying trials.  
 
A decrease in CSF A42 is postulated to be the earliest biochemical change in AD (Palmqvist et al., 
2016). However, CSF total tau (t-tau) may be considered more clinically relevant and a disease 
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intensity marker; the higher the concentration, the more intense the neurodegenerative process 
(Samgard et al., 2010). Using ultrasensitive measurement techniques, the protein can be measured in 
plasma and efforts have been made to clarify the role of plasma t-tau in AD. There is general 
agreement that concentrations are increased (Olsson et al., 2016) but the overlap between clinical 
groups is larger than for CSF tau (Zetterberg et al., 2013). In addition, the correlation of plasma with 
CSF tau is weak (Mattsson et al., 2016b). Plasma tau concentrations, in contrast to CSF, may be 
confounded by the rapid degradation of tau in blood; the half-life of tau in plasma is hours (Randall et 
al., 2013) compared to weeks in the CSF (Sato et al., 2018), but also by extra-cerebral tau mRNA and 
protein expression (www.proteinatlas.org/ENSG00000186868). It is possible that some CNS-derived 
proteins are eventually excreted into body fluids other than CSF and blood. The presence of tau 
species in saliva has been demonstrated using mass spectrometry (Shi et al., 2011). However, the 
relationship between salivary concentrations of t-tau and processes within the CNS is far from clear, 
and no conclusive data on disease association have been reported so far. In this study, we examined 
the diagnostic accuracy of salivary t-tau concentration for AD in dementia and mild cognitive 
impairment (MCI) patients as compared to healthy elderly control (HEC) individuals. Furthermore, 
we investigated the relationship of salivary t-tau concentration with neurophysiological and MRI 
measures.   
 
MATERIAL AND METHODS – Saliva samples of 160 HECAD, 60 68 MCI and 54 53 HEC AD 
participants were obtained from a single centre from the AddNeuroMed consortium (Kings Health 
Partners-Dementia Case Register (KHP-DCR)) (Lovestone et al., 2009). Details regarding clinical 
diagnosis, cognitive assessments, APOE genotyping and magnetic resonance imaging (MRI) 
acquisition have been previously described (Hye et al., 2014). Overnight fasting was required from all 
participants and the mouth was rinsed thoroughly 10 minutes prior to collection. Unstimulated whole 
saliva was collected into sterile plastic containers precoated with 2% sodium azide solution. 
Unstimulated Samples saliva was were collected into preweighed sterile plastic 30 mL containers at 
30 second intervals for 2 minutes or until 2 mL had been achieved. Samples were centrifuged for 10 
minutes (500xg at 4°C) placed on ice andfor the removal of debris removed by a low spin (500× g for Formatted: Font: Italic
10 minutes) at 4°C. Aliquoted 100 μL samples (avoiding the pellet) were immediately stored at -80°C. 
Saliva samples were thawed on ice, diluted 4-times and measured in duplicate for t-tau concentration 
using the commercially available Human Total Tau assay on an HD-1 Simoa instrument (Quanterix, 
Lexington, MA) (Randall et al., 2013). Statistical analysis was performed by using IBM SPSS 
Statistics, version 25 (Armonk, NY, USA). Associations between salivary t-tau and demographic 
factors were assessed and a generalised linear model (GLM) corrected for the significant differences 
of age and years of education between in the diagnostic groups (Table 1). The differences of salivary 
t-tau concentrations between diagnostic groups were calculated by Analysis of variance (ANOVA). 
Correlations between adjusted salivary t-tau levels,  and MMSE and MRI regional measures were 
calculated using pearson r.  
 
CORE DATA – The demographics for the study population are detailed in Table 1. Salivary t-tau 
was above of the lower limit of quantification (LoQ) quantifiable in 96.1% of participants included in 
the study (Supplementary Table 1), with an average coefficient of variation of 11.5% for duplicate 
measurements. Salivary t-tau was not significantly associated with age (r = 0.080, P = 0.190), years of 
education (r = -0.033, P = 0.586) or , sex (median, 9.6 ng/L for females versus 12.3 ng/L for males; P 
= 0.872) or APOE ε4 genotype (median, 8.1 ng/L in non-carriers versus 9.7 ng/L in carriers; P = 
0.788). We observed a non-significant increase of salivary t-tau concentration across diagnostic 
groups (median, 9.6 ng/L for HEC, 9.8 ng/L for MCI and 12.2 ng/L for AD; P = 0.219, Fig. 1). This 
was also reflected by non-significant associations of increased salivary t-tau with poorer global 
cognitive performance as assessed with MMSE (r = -0.077, P = 0.198) and CDR sum of boxes (CDR-
SoB) (median, 8.7 ng/L for CDR=0 and 10.2 ng/L CDR=<0.5; P = 0.314). There was no association 
between salivary t-tau concentration and measures of ventricular volume (r = -0.048, P = 0.784), 
hippocampal volume (r = 0.068, P = 0.686) and , entorhinal cortical thickness (r = 0.088, P = 0.292) . 
and entorhinal cortex volume (r = 0.107, P = 0.458). However, when the AD group was analysed 
separately, a nominal association of lower salivary t-tau with greater ventricular volume was observed 
(ρ r = -0.492, P = 0.045).  
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DISCUSSION – We observed no statistically significant difference in the concentrations of salivary 
t-tau across diagnostic groups. Additionally, we demonstrated that there was no association of salivary 
t-tau with MMSE and CDR-SoB sum of boxes, although the trends observed might indicate higher 
salivary t-tau with poorer cognition. In a subset, MRI measures were not associated with salivary t-
tau. However, in the AD group alone, larger ventricle size was nominally associated with salivary t-
tau concentration.  
 
The only otherfirst study examining salivary tau in AD equally reported no difference in t-tau between 
aged-matched controls and AD (Shi et al., 2011). However, Shi et al also reported an increased ratio 
of salivary p-tau to t-tau (Shi et al., 2011). One explanation for these contradicting results is the 
difference in analytical methods used. In our study, the Simoa assay employed uses a combination of 
antibodies that react with both normal and phosphorylated tau with epitopes in the mid- and N-
terminal regions of the molecule (Mattsson et al., 2016a), making the assay specific for most tau 
isoforms. Shi et al. used a Luminex assay (based on mid-domain antibodies) that measures the 
phosphorylated proportion (p-tau-181) separately from t-tau and it was the p-tau/t-tau ratio that was 
increased in AD in their study. Moreover, Pekeles et al using western blot found the p-tau/t-tau ratio  
using one specific phosphorylation site (pS396) to be increased in AD (Pekeles et al., 2018 
https://doi.org/10.1016/j.dadm.2018.03.003)   
 
At present, it is hard to imagine how sampling of saliva could produce results with a clear link to 
changes in the brain, given the many biological barriers and compartments the marker has to cross on 
its way to the sampling site. Furthermore, expression of, for example, tau mRNA and protein in 
salivary glands and other extra-cerebral tissues such as the kidney (tau data in the Human Protein 
Atlas) could further limit the interpretability of t-tau measurements in saliva. Nevertheless, saliva has 
certain advantages over blood and CSF as a fluid for biomarker assessment. Its collection is less 
invasive and it is a minimally complex matrix that does not clot. Functions of the saliva are not only 
restricted to digestion. Saliva contains a large collection of proteins involved in the immune defence 
and the neuroendocrine system (Jasim et al., 2016). Further, it contains peptides that are in common 
with the CSF (Jasim et al., 2016). It is also possible that the innervations of the salivary gland could 
provide a more direct link between the saliva and the CNS than via the blood. The submandibular 
gland is responsible for the vast majority of total resting and stimulated salivary volume and has been 
reported to be dysfunctional in AD (Ship et al., 1990). Significantly lower levels of tau pS396 and 
pT231 but not t-tau has been observed in the submandibular gland of AD patients (Dugger et al., 
2016). Therefore, saliva could be a rich source of novel biomarkers for AD, for example lactoferrin 
(Carro et al., 2017), but there are major challenges in standardisation of collection and pre-processing 
methods ahead. 
 
There are limitations to this study. Firstly, we are inferring that the AD patients in this study do 
indeed have increased tau pathology and further clarification should seek to correlate salivary t-tau 
concentrations with CSF or PET measures. Similar studies investigating alpha-synuclein in 
Parkinson’s disease demonstrate no relationship between saliva and CSF concentrations (Goldman et 
al., 2018). Secondly, although the largest study of salivary tau to date, the disproportionate numbers 
between the diagnostic groups could have potentially masked meaningful group differences, as we 
observe a non-significant median elevation in AD patients. Lastly, we can only report the usefulness 
of salivary t-tau alone and that a salivary t-tau/p-tau ratio or p-tau alone should be investigated further 
as a potential biomarker for AD. In summary, t-otal tau is reliably measured in human saliva using the 
Simoa platform and exists in a range of concentrations that are not systematically different between 
AD and non-AD diagnostic groups. We conclude that salivary t-tau is not a reliable biomarker for 
AD, nor a surrogate measure of cognition or brain atrophy. 
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Table 1. Summary of the demographic and clinical data of study participants 
 
Healthy Elderly 
Controls (n = 160) 
Mild Cognitive 
Impairment (n = 68) 
Alzheimer’s disease 
(n = 53) 
P value 
Age, y (s.d) 78.0 (6.7) 79.8 (7.4) 81.4 (6.6) 0.006 
Sex, male/female (% 
female) 
66/94 (758.7) 33/35 (51.5) 23/30 (56.6) ns 
Education, y (s.d) 13.9 (3.4) 12.1 (3.3) 11.7 (2.5) >0.001 
APOE genotype (% 
ε4 carriers) {missing} 
26 (32) {79} 9 (42.8) {47} 14 (58.3) {26} 0.041 
MMSE (s.d) 28.9 (1.1) 26.8 (2.3) 22.3 (5.7) >0.001 
CDR [sum of boxes] 
(s.d, range) 
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 Figure 1. Salivary total tau concentrations in healthy elderly controls (HEC), patients with 
mild cognitive impairment (MCI), and patients with Alzheimer’s disease (AD). 




Reviewer #2: 1) container with sodium azide solution was used. It has been shown to affect measurement in a 
few saliva biomarkers using immunoassay. Any effect of sodium azide inclusion on the measurement of the 
salivary total tau using the platform in this study? 
We thank the reviewer for pointing out this important feature of the article. Firstly, to address the question, we 
have gone back to the dental study were these samples were obtained with Professor Mark Ide (co-author). In 
fact, samples collected for this particular study were collected without any preservative. We apologize for this 
error in reporting and we have changed the manuscript to reflect this. 
 
“Unstimulated saliva was collected into preweighed sterile plastic 30 mL containers at 30 second intervals for 
2 minutes or until 2 mL had been achieved” 
 
Co-authors of this paper are members of a working group for saliva standardization in the Alzheimer 
Association. We are therefore going to perform a side-by-side comparison on the effects of sodium azide in 
saliva analysis (as sodium azide has been used in saliva biomarker publications) as information for the field.  
 
2) It is clear that total tau species had no significant changes in AD vs controls across saliva samples from 
various saliva studies including this. 
Although there is issue regarding the reliability of assay and measurement platforms, there should not be a 
presumption that salivary p-tau species would turn out just as negative results as total salivary tau if they were to 
be measured in this study. In fact there have been consistent significant differences in p-Tau species across 
various biofluids including saliva. The suggestions for author would be 1) to address this as one limitation of this 
study as no concurrent measurement of t-Tau and p-Tau species are feasible. 2) In the last paragraph, to guide 
the field in presenting the issue as a future direction to work on. 3) Most importantly,since this is a negative 
results paper, on one hand it is wise to guide the field to avoid replication, it is equally if not more important to 
not dismiss the potential utility of p-Tau as a biomarker of AD just because t-Tau is not significant.  
 
We thank the reviewer for these comments and we agree that although our data show salivary t-tau is not a 
biomarker for AD, no conclusions can be made on p-tau. Is this something we are going to follow up, but 
unfortunately cannot be performed in the same cohort. We are also going to investigate novel tau fragments that 
our group has been investigating in CSF. We have added an additional sentence in the discussion to reflect the 
comments made by the reviewer above. 
 
“Lastly, we can only report the usefulness of salivary t-tau alone and that a salivary t-tau/p-tau ratio or p-tau 







Re: Response to reviewers for submission to Neurobiology of ageing 
 
Dear Dr. Rapp and reviewers, 
 
Please find enclosed an edited manuscript and response to the reviewers for the entitled article, “No association 
of salivary total tau concentration with Alzheimer’s disease” by Ashton NJ et al., to be submitted as a negative 
result to Neurobiology of ageing. I can confirm that all co-authors have contributed and approved the changes to 
the manuscript and the rebuttal. 
 
We are very grateful for the time taken by the reviewers to generate insightful and helpful suggestions for this 
article. We hope that the edits to manuscript text and the explanations that accompany these edits are satisfactory 
to the reviewers and clarify any original concerns. We have made some minor changes to the structure of the 
original manuscript; 
 
 Figure 1 has been removed from the main text and added a separate TIF file. The Figure legend remains 
in the manuscript text.   
 Figure 1 axis label “control” has been re-labelled as “HEC” to be consist with the manuscript text 
 Supplementary Table 1 has been added at the request of the reviewers.  




Dr. Nicholas Ashton and Professor Henrik Zetterberg on behalf of the authors 
 
Corresponding author: 
Dr. Nicholas Ashton; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, 
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